
can you share the preclinical work you describe along with the papers?
— James Brandt (@jmsbrandt) November 20, 2020
can you share the preclinical work you describe along with the papers?
— James Brandt (@jmsbrandt) November 20, 2020
No, stinging isn't the issue, it is a 4% solution given continuously that broadly inhibits phosphatases. This will have cumulative effects.
— Drugs (@drug_smolecules) November 30, 2020
The hyperemia is at 18% with 7 days of follow up
Rhopressa has only 50-60% of their hyperemia events show up prior to 24 days (~20%)
So I think all $arpo investors should understand that $aeri data being comped is in a fixed dose combination. Showing a 1.4mmHg reduction as a second drop is not even close to commercially viable.
— Patrick Sikorski (@pharmacreep) December 1, 2020
Thanks Sentiv!
— brendan (@brendan_49) November 30, 2020
I'm curious about your long-term big picture view of glaucoma. Especially curious about impact of effective $OCUL style 1-2/year injections on the need for adjunctive therapies. How much unmet need is there once compliance is perfected?